Reimbursement for Somatuline^® Depot (lanreotide) Injection

Somatuline^® Depot (lanreotide) Injection-a recognized medical advancement for acromegaly-is available through leading specialty pharmacies and will be covered by most insurance company pharmacy benefit plans. The average out-of-pocket costs for Somatuline^® Depot (lanreotide) Injection are comparable to those of other long-acting somatostatin analogs for acromegaly.

A convenient reimbursement hotline, TerciCare^SM, will help you determine your copay and find out where you can get the product.

Just call 1-866-TERCICA (1-866-837-2422).

Resources for information and support

Remember that you are not alone in having acromegaly, and you can always take advantage of resources for information and support.

Glossary of terms

Find the meanings of any terms used in this Web site that you may not understand in the glossary.

Watch a short video about injecting Somatuline^® Depot (lanreotide) Injection

See how easy it is to inject Somatuline^® Depot (lanreotide) Injection. To view a brief video, click here.

IMPORTANT SAFETY INFORMATION

Somatuline^® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline^® Depot (lanreotide) Injection may experience hypoglycemia or hyperglycemia. Glucose levels monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline^® Depot (lanreotide) Injection 60mg.

There are no adequate and well controlled studies in pregnant women. Because animal reproduction studies are no always predictive of human responses, Somatuline^® Depot (lanreotide) Injection should be used during pregnancy only if the potential benefit justifies risk to the fetus. A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline^® Depot (lanreotide) Injection may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline^® Depot (lanreotide) Injection may reduce the intestinal absorption of co-administered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea, cholelithiasis, abdominal pain, nausea, injection site reaction, flatulence, arthralgia, and loose stools.

Please see Full Prescribing Information for additional important information.

SOMATULINE^® DEPOT (LANREOTIDE) INJECTION IS MARKETED BY TERCICA, INC. AND MANUFACTURED BY IPSEN PHARMA BIOTECH (SIGNES, FRANCE).

View our injection video

Resources for information and support

Glossary of terms

Watch a short video about injecting Somatuline® Depot (lanreotide) Injection

IMPORTANT SAFETY INFORMATION

Watch a short video about injecting Somatuline^® Depot (lanreotide) Injection